Compare Morgan Stanley (MS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs TG Therapeutics Inc — how do they compare? Morgan Stanley trades at $190.02 (market cap $294.39B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Morgan Stanley is far larger — about 36.1× TG Therapeutics Inc's market cap, and Morgan Stanley pays a 2.45% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 92 Days and TG Therapeutics Inc for 16 Days on average.
| MS | TGTX | |
|---|---|---|
Market Cap | $294.39B | $8.16B |
Volume | 5,836,423 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $228.42 | $59.06 |
52-Week Low | $151.86 | $26.94 |
Typical Hold Time | 92 Days | 16 Days |
Enterprise Value | $660.04B | $8.37B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $187.41, down 1.21% on the day, with a bearish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing to $66.0 billion in 2025 and net income reaching $16.9 billion, alongside three consecutive quarterly EPS beats. Analysts maintain a bullish stance with a $229.25 consensus price target, citing growth in wealth management and AI financing.
The outlook is positive given earnings momentum and strategic growth areas, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to analyst targets if execution continues, though macroeconomic and capital markets volatility pose headwinds.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
